Seminar Systemic sclerosis : hypothesisdriven treatment strategies, 2006. ,
Epidemiology of systemic sclerosis, Best Practice & Research Clinical Rheumatology, vol.24, issue.6, pp.857-869, 2010. ,
DOI : 10.1016/j.berh.2010.10.007
Prevalence of systemic sclerosis in a French multi-ethnic county, Rheumatology, vol.43, issue.9, pp.1129-1137, 2004. ,
Systemic sclerosis: Markers and targeted treatments, Acta Reumatol. Port, vol.2016, issue.1, pp.18-25, 2016. ,
Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies, Rheumatology, vol.29, issue.1, pp.1462-0332, 2012. ,
DOI : 10.1111/j.1445-5994.1999.tb01587.x
Mortality and survival in systemic sclerosis: Systematic review and meta-analysis, Seminars in Arthritis and Rheumatism, vol.44, issue.2, pp.208-219, 2014. ,
DOI : 10.1016/j.semarthrit.2014.05.010
Autoanticorps au cours de la sclérodermie systémique: intérêt clinique et approche diagnostique, pp.273-281 ,
Preliminary criteria for the classification of systemic sclerosis (scleroderma), Arthritis & Rheumatism, vol.52, issue.5, 1980. ,
DOI : 10.1001/archderm.1943.01500210084005
Criteria for the classification of early systemic sclerosis, J. Rheumatol, vol.28, issue.7, pp.1573-1579, 2001. ,
Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature, Autoimmunity Reviews, vol.13, issue.2, pp.151-156, 2014. ,
DOI : 10.1016/j.autrev.2013.10.002
Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies, Arthritis & Rheumatism, vol.22, issue.7, pp.1956-1963, 2003. ,
DOI : 10.1111/j.0954-6820.1982.tb01929.x
Genomic and genetic studies of systemic sclerosis: A systematic review, Human Immunology, vol.78, issue.2, pp.153-165, 2017. ,
DOI : 10.1016/j.humimm.2016.10.017
Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up, Hum. Mol. Genet, vol.21, issue.12, pp.2825-2860, 2012. ,
on disease susceptibility and related pulmonary fibrosis, Arthritis & Rheumatism, vol.71, issue.Pt 2, pp.2472-2479, 2009. ,
DOI : 10.4049/jimmunol.182.1.34
BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians, Annals of the Rheumatic Diseases, vol.69, issue.4, pp.700-705, 2010. ,
DOI : 10.1136/ard.2009.118174
Les ulc??res digitaux de la scl??rodermie syst??mique, Annales de Dermatologie et de V??n??r??ologie, vol.138, issue.11, pp.762-770, 2011. ,
DOI : 10.1016/j.annder.2011.06.011
Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis, Journal of Cellular and Molecular Medicine, vol.120, issue.6a, pp.1241-1254, 2010. ,
DOI : 10.1161/CIRCULATIONAHA.109.855114
Dysregulation of angiogenic homeostasis in systemic sclerosis, International Journal of Rheumatic Diseases, vol.71, issue.9, pp.448-454, 2013. ,
DOI : 10.1136/annrheumdis-2011-200657
Elevated vascular endothelial growth factor in systemic sclerosis, J. Rheumatol, vol.30, issue.7, pp.1529-1562, 2003. ,
Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis, Circulation Research, vol.95, issue.1, pp.109-116, 2004. ,
DOI : 10.1161/01.RES.0000134644.89917.96
The anti-angiogenic isoforms of VEGF in health and disease, Biochemical Society Transactions, vol.37, issue.6, pp.1207-1213, 2009. ,
DOI : 10.1042/BST0371207
b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis, Annals of the Rheumatic Diseases, vol.27, issue.8, pp.1425-1427, 2013. ,
DOI : 10.1136/annrheumdis-2011-200837
Overexpression of VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis, Circulation Research, vol.109, issue.3, pp.14-26, 2011. ,
DOI : 10.1161/CIRCRESAHA.111.242057
Review: Evidence That Systemic Sclerosis Is a Vascular Disease, Arthritis & Rheumatism, vol.170, issue.Suppl 3, pp.1953-1962, 2013. ,
DOI : 10.1164/rccm.200308-1151OC
Endothelial Progenitor Cells for Vascular Regeneration, Journal of Hematotherapy & Stem Cell Research, vol.11, issue.2, pp.171-178, 2002. ,
DOI : 10.1089/152581602753658385
URL : http://www.rbm.hiroshima-u.ac.jp/rcm-coe/file/fourth/pdf/Asahara.pdf
Transcriptional Regulation of Bim by FOXO3a and Akt Mediates Scleroderma Serum???Induced Apoptosis in Endothelial Progenitor Cells, Circulation, vol.118, issue.21, pp.2156-2165, 2008. ,
DOI : 10.1161/CIRCULATIONAHA.108.787200
The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis., Journal of Clinical Investigation, vol.101, issue.10, pp.2029-2064, 1998. ,
DOI : 10.1172/JCI2261
Antiendothelial Cell Antibodies Induce Apoptosis of Bone Marrow Endothelial Progenitors in Systemic Sclerosis, The Journal of Rheumatology, vol.37, issue.10, pp.2053-2063, 2010. ,
DOI : 10.3899/jrheum.091346
Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations, Clin. Exp. Rheumatol, vol.26, issue.3, pp.421-429, 2008. ,
Association between endothelial function and microvascular changes in patients with secondary Raynaud???s phenomenon, Clinical Rheumatology, vol.45, issue.11, 2014. ,
DOI : 10.1093/rheumatology/kel310
Increased Factor VIII/von Willebrand Factor Antigen and von Willebrand Factor Activity in Scleroderma and in Raynaud's Phenomenon, Annals of Internal Medicine, vol.94, issue.4_Part_1, pp.482-484, 1981. ,
DOI : 10.7326/0003-4819-94-4-482
Plasma Thrombomodulin as a Marker of Vascular Injuries in Collagen Vascular Diseases, American Journal of Clinical Pathology, vol.101, issue.1, pp.109-113, 1994. ,
DOI : 10.1093/ajcp/101.1.109
Endothelin-1 Levels in Scleroderma Patients: A Pilot Study, ISRN Dermatology, vol.183, issue.1, p.125632, 2013. ,
DOI : 10.1111/j.1346-8138.2011.01299.x
Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action, Arthritis & Rheumatism, vol.159, issue.8, pp.978-83, 1991. ,
DOI : 10.1111/j.1349-7006.1989.tb02310.x
Raynaud's Phenomenon and Plasma Endothelin: Correlations with Capillaroscopic Patterns in Systemic Sclerosis, The Journal of Rheumatology, vol.36, issue.6, pp.1235-1239, 2009. ,
DOI : 10.3899/jrheum.081030
Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs, Circulation, vol.102, issue.19, pp.2434-2440, 2000. ,
DOI : 10.1161/01.CIR.102.19.2434
Bosentan in pulmonary arterial hypertension secondary to scleroderma, J. Rheumatol, vol.33, issue.1, pp.61-68, 2006. ,
Meta-Analysis of Healing and Prevention of Digital Ulcers in Systemic Sclerosis, Arthritis Care & Research, vol.7, issue.Suppl, pp.1460-1471, 2013. ,
DOI : 10.1093/rheumatology/ken001
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database, Annals of the Rheumatic Diseases, vol.71, issue.8, pp.1355-1360, 2012. ,
DOI : 10.1136/annrheumdis-2011-200742
Digital ulcers: overt vascular disease in systemic sclerosis, Rheumatology, vol.65, issue.suppl_3, pp.19-24, 2006. ,
DOI : 10.1056/NEJM199104183241618
URL : https://academic.oup.com/rheumatology/article-pdf/48/suppl_3/iii19/18096586/kep105.pdf
Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis, Clinical Rheumatology, vol.49, issue.2, pp.207-214, 2014. ,
DOI : 10.1093/rheumatology/keq291
Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry, Annals of the Rheumatic Diseases, vol.71, issue.5, pp.718-721, 2012. ,
DOI : 10.1136/annrheumdis-2011-200631
Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry, Arthritis Care & Research, vol.60, issue.Suppl 29, pp.142-149, 2011. ,
DOI : 10.1002/art.24333
Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors, Br. J. Dermatol, vol.160, issue.4, pp.835-878, 2009. ,
Clinical Features of Scleroderma Patients With or Without Prior or Current Ischemic Digital Ulcers: Post-Hoc Analysis of a Nationwide Multicenter Cohort (ItinerAIR-Sclerodermie), The Journal of Rheumatology, vol.36, issue.7, pp.1470-1476, 2009. ,
DOI : 10.3899/jrheum.081044
Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study, Arthritis & Rheumatology, vol.25, issue.Suppl 91, pp.2527-2566, 2016. ,
DOI : 10.1002/sim.2680
Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry Clin ,
Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis, Annals of the Rheumatic Diseases, vol.67, issue.1, pp.120-123, 2008. ,
DOI : 10.1136/ard.2007.072686
Digital ulcers predict a worse disease course in patients with systemic sclerosis, Ann. Rheum. Dis, 2014. ,
Mapping and predicting mortality from systemic sclerosis, Ann. Rheum. Dis, pp.2017-211448, 2017. ,
Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort, Annals of the Rheumatic Diseases, vol.71, issue.(Suppl 76), pp.1736-1776, 2016. ,
DOI : 10.1136/annrheumdis-2011-200631
Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry, Fonollosa-Pla, and RESCLE Investigators, pp.200-208, 2016. ,
DOI : 10.1016/j.semarthrit.2016.04.007
Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions ,
Calcium channel blockers for primary Raynaud's phenomenon, Cochrane Database of Systematic Reviews, p.2069, 2014. ,
Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis, Rheumatology, vol.15, issue.5, pp.145-150, 2005. ,
DOI : 10.1097/00005344-199005000-00023
Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?, British Journal of Clinical Pharmacology, vol.19, issue.1, pp.83-92, 2007. ,
DOI : 10.1177/00912700122010654
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2007.02851.x/pdf
Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study., BMJ, vol.298, issue.6673, pp.561-565, 1989. ,
DOI : 10.1136/bmj.298.6673.561
L???iloprost dans le traitement de la scl??rodermie syst??mique, La Presse M??dicale, vol.37, issue.5, pp.831-839, 2008. ,
DOI : 10.1016/j.lpm.2007.06.016
Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study, Annals of Internal Medicine, vol.120, issue.3, pp.199-206, 1994. ,
DOI : 10.7326/0003-4819-120-3-199402010-00004
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease, Annals of Internal Medicine, vol.132, issue.6, pp.425-459, 2000. ,
DOI : 10.7326/0003-4819-132-6-200003210-00002
Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis., Annals of the Rheumatic Diseases, vol.47, issue.1, pp.43-50, 1988. ,
DOI : 10.1136/ard.47.1.43
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis, J. Rheumatol, vol.19, issue.9, pp.1407-1421, 1992. ,
A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases., Annals of the Rheumatic Diseases, vol.50, issue.11, pp.800-804, 1991. ,
DOI : 10.1136/ard.50.11.800
Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study, Clin Exp Rheumatol, vol.19, pp.503-511, 2001. ,
Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost, Joint Bone Spine, vol.73, issue.1, pp.57-61, 2006. ,
DOI : 10.1016/j.jbspin.2005.04.006
Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year, Rev. Rhum. Engl. Ed, vol.65, issue.12, pp.745-50, 1998. ,
Systemic Sclerosis Therapy with Iloprost: A Prospective Observational Study of 30 Patients Treated for a Median of 3 Years, Clinical Rheumatology, vol.21, issue.3, pp.244-50, 2002. ,
DOI : 10.1007/PL00011223
Diseasemodifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group, Clin. Exp. Rheumatol, vol.25, issue.5, pp.722-729 ,
[Longterm effects of cyclic therapy with iloprost in systemic sclerosis], Reumatismo, vol.60, issue.2, pp.114-123 ,
A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost, Clinical Rheumatology, vol.42, issue.Suppl 29, pp.807-813, 2009. ,
DOI : 10.1177/1358836X9800300105
Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost, Rheumatology International, vol.66, issue.suppl 29, pp.1933-1938, 2012. ,
DOI : 10.1136/ard.2006.066068
AB0623???Treatment of Scleroderma-Related Digital Ulcers with Iloprost: A Cohort Study, Annals of the Rheumatic Diseases, vol.75, issue.Suppl 2, pp.1117-1117, 2016. ,
DOI : 10.1136/annrheumdis-2016-eular.2228
Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen, Rheumatology International, vol.120, issue.2, pp.245-249, 2017. ,
DOI : 10.7326/0003-4819-120-3-199402010-00004
Perfusions intraveineuses d'Iloprost : profil des patients et tolérance, 2013. ,
Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates, Blood Transfus, vol.11, issue.3, pp.391-400, 2013. ,
Effect of Hemodilution In Vitro with Hydroxyethyl Starch on Hemostasis, Medical Science Monitor, vol.23, pp.2189-2197, 2017. ,
DOI : 10.12659/MSM.901588
A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation., British Journal of Ophthalmology, vol.69, issue.2, pp.108-124, 1985. ,
DOI : 10.1136/bjo.69.2.108
Haemodilution for acute ischaemic stroke, Cochrane database Syst. Rev, vol.16, issue.23, p.103, 2014. ,
DOI : 10.1161/01.STR.16.5.765
URL : http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000103.pub2/pdf
Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx, Critical Care, vol.105, issue.5, p.538, 2014. ,
DOI : 10.1007/s00395-010-0118-z
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy, Circulation, vol.112, issue.19, pp.2980-2985, 2005. ,
Phosphodiesterase Type 5 Inhibition Is a Novel Therapeutic Option in Raynaud Disease, Archives of Internal Medicine, vol.166, issue.2, p.231, 2006. ,
DOI : 10.1001/archinte.166.2.231
Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor [abstract], Ann Rheum Dis, vol.64258, issue.64, p.258, 2005. ,
Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis, The Journal of Rheumatology, vol.36, issue.10, pp.2264-2268, 2009. ,
DOI : 10.3899/jrheum.090270
Efficacy of tadalafil in secondary Raynaud???s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial, Rheumatology, vol.60, issue.12, pp.2420-2428, 2010. ,
DOI : 10.1002/art.24333
Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study, Annals of the Rheumatic Diseases, vol.69, issue.8, pp.1475-1483, 2010. ,
DOI : 10.1136/ard.2009.116475
BSR and BHPR guideline for the treatment of systemic sclerosis, Rheumatology, vol.32, issue.6, pp.1906-1916, 2016. ,
DOI : 10.1001/jama.2014.6368
A prospective study of the use of botulinum toxin injections in the treatment of Raynaud???s syndrome associated with scleroderma, Journal of Hand Surgery (European Volume), vol.281, issue.8, pp.876-880, 2014. ,
DOI : 10.1097/01.prs.0000244860.00674.57
Botulinum Toxin Type A: A Treatment Option for Digital Ischemia in Patients With Raynaud's Phenomenon, The Journal of Hand Surgery, vol.34, issue.3, pp.446-52, 2009. ,
DOI : 10.1016/j.jhsa.2008.11.026
Botox Therapy for Ischemic Digits, Plastic and Reconstructive Surgery, vol.124, issue.1, pp.191-201, 2009. ,
DOI : 10.1097/PRS.0b013e3181a80576
URL : https://doi.org/10.1016/j.jvs.2009.12.053
Int??r??t de la toxine botulinique de type A dans le traitement des syndromes de Raynaud s??v??res secondaires ?? la scl??rodermie syst??mique, Annales de Chirurgie Plastique Esth??tique, vol.58, issue.6, pp.658-662, 2013. ,
DOI : 10.1016/j.anplas.2011.11.001
Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study, The Journal of Dermatology, vol.149, issue.1, pp.56-62, 2016. ,
DOI : 10.1016/j.pain.2010.02.024
Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up, Rheumatology, vol.31, issue.2, pp.301-306, 2016. ,
DOI : 10.1002/art.10486
URL : https://hal.archives-ouvertes.fr/hal-01452751
Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients, Curr. Res. Transl. Med, vol.65, issue.1, pp.40-43, 2017. ,
Digital Sympathectomy in Patients With Scleroderma, Annals of Plastic Surgery, vol.75, issue.6, pp.637-643, 2015. ,
DOI : 10.1097/SAP.0000000000000614
Long-term follow-up of periarterial sympathectomy for chronic digital ischaemia, Journal of Hand Surgery (European Volume), vol.3, issue.8, pp.788-93, 2012. ,
DOI : 10.1097/00000658-198106000-00004
Extended Periarterial Sympathectomy: Evaluation of Long-Term Outcomes, HAND, vol.1, p.155894471771511, 2017. ,
DOI : 10.1097/00000658-198106000-00004
Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist, Arthritis Rheum, vol.50, issue.12, pp.3985-3993, 2004. ,
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial, Annals of the Rheumatic Diseases, vol.70, issue.1, pp.32-40, 2011. ,
DOI : 10.1136/ard.2010.130658
Optimal management of digital ulcers in systemic sclerosis, Ther. Clin. Risk Manag, vol.11, pp.939-947, 2015. ,
Update of EULAR recommendations for the treatment of systemic sclerosis, Ann. Rheum. Dis, vol.76, issue.8, pp.1327-1339, 2017. ,
Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry, Annals of the Rheumatic Diseases, vol.31, issue.(Suppl 76), pp.1770-1776, 2016. ,
DOI : 10.1016/j.jbspin.2009.05.015
Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis, J. Rheumatol, vol.41, issue.7, pp.1317-1323, 2014. ,
Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study, J. Rheumatol, vol.34, issue.12, pp.2423-2453, 2007. ,
Assessing disability and quality of life in systemic sclerosis: Construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey, Arthritis & Rheumatism, vol.103, issue.1, pp.94-102, 2007. ,
DOI : 10.7326/0003-4819-118-8-199304150-00009
[Systemic sclerosis and occupational difficulties: Results of a prospective study], La Rev. Med. interne, 2017. ,
Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis, Acta Derm. Venereol, vol.76, issue.3, pp.236-244, 1996. ,
Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study, J. Rheumatol, vol.35, issue.9, pp.1830-1837, 2008. ,
Administration d'ilomédine au sein d'une cohorte de 30 patients atteints d'ischémie digitale : évaluation des pratiques professionnelles et détermination de critères de bonne tolérance clinique, 2009. ,
Administration d???iloprost au sein d???une cohorte de 30??patients atteints d???isch??mie digitale??: d??termination de crit??res de bonne tol??rance clinique, La Revue de M??decine Interne, vol.31, issue.S1, p.78, 2010. ,
DOI : 10.1016/j.revmed.2010.03.443
Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes, J. Rheumatol, vol.26, issue.10, pp.2173-2181, 1999. ,
Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study, Annals of the Rheumatic Diseases, vol.353, issue.6, pp.1009-1015, 2016. ,
DOI : 10.1056/NEJMoa050010
URL : https://hal.archives-ouvertes.fr/hal-01466199
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon, Arthritis & Rheumatism, vol.42, issue.9, pp.2410-2420, 2002. ,
DOI : 10.1002/1529-0131(199911)42:11<2372::AID-ANR16>3.0.CO;2-J
Validation and comparison of reference equations for the 6-min walk distance test, European Respiratory Journal, vol.31, issue.3, pp.571-578, 2008. ,
DOI : 10.1183/09031936.00104507